Fingerprint
Dive into the research topics of 'Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically